Press release
Neurotrophic Keratopathy Market to Expand Significantly by 2032, States DelveInsight Report | ReGenTree, LLC, Oyster Point Pharma, Inc., Dompé Farmaceutici, Syneos Health
To Know in detail about the Neurotrophic Keratopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurotrophic Keratopathy Market Forecast
https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Neurotrophic Keratopathy Market Report:
• The Neurotrophic Keratopathy market size was valued approximately USD 350 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In April 2025, OKYO Pharma confirmed that urcosimod, previously known as OK-101, maintains stability for over two and a half years in single-use ampoules designed for patient use. This achievement marks a significant advancement in supporting the drug's long-term potential as it moves through clinical development. Urcosimod is currently undergoing a Phase 2b clinical trial-a randomized, placebo-controlled, double-masked study with 48 participants-aimed at evaluating its efficacy in treating neurotrophic keratopathy (NCP), a severe and progressive degenerative eye condition.
• In the 7MM, there were over 138,000 NK cases overall in 2022. It is anticipated that the number of Neurotrophic Keratopathy cases in the 7MM will rise between 2023 and 2032, the prediction period.
• In 2022, out of the seven largest markets, the EU4 and the UK accounted for around 43% of the instances of Neurotrophic Keratopathy
• In the 7MM, there were around 102,000 individuals with Neurotrophic Keratopathy diagnosis overall in 2022. These cases are anticipated to rise as new medicines are approved and awareness is increased.
• The US achieved its greatest prevalence and diagnosed population of Neurotrophic Keratopathy in the 7MM in 2022.
• Key Neurotrophic Keratopathy Companies: ReGenTree, LLC, Oyster Point Pharma, Inc., Dompé Farmaceutici, Syneos Health, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, and others
• Key Neurotrophic Keratopathy Therapies: RGN-259, OC-01 (varenicline), cenegermin-bkbj, Udonitrectag, rhNGF, REC 0559, CSB-001, and others
• The Neurotrophic Keratopathy epidemiology based on gender analyzed that most of the Neurotrophic Keratopathy cases comprise of the female population
• The Neurotrophic Keratopathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurotrophic Keratopathy pipeline products will significantly revolutionize the Neurotrophic Keratopathy market dynamics.
Neurotrophic Keratopathy Overview
The rare degenerative corneal disease known as Neurotrophic Keratopathy (NK), also referred to as Neurotrophic Keratitis, is characterized by symptoms such as diminished or absent corneal feeling, impaired healing, and corneal epithelial breakdown, which increases the corneal surface's vulnerability to damage and compromised healing.
Get a Free sample for the Neurotrophic Keratopathy Market Report
https://www.delveinsight.com/report-store/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Neurotrophic Keratopathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Neurotrophic Keratopathy Epidemiology Segmentation:
The Neurotrophic Keratopathy market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Neurotrophic Keratopathy
• Prevalent Cases of Neurotrophic Keratopathy by severity
• Gender-specific Prevalence of Neurotrophic Keratopathy
• Diagnosed Cases of Episodic and Chronic Neurotrophic Keratopathy
Download the report to understand which factors are driving Neurotrophic Keratopathy epidemiology trends @ Neurotrophic Keratopathy Epidemiology Forecast
https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Neurotrophic Keratopathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neurotrophic Keratopathy market or expected to get launched during the study period. The analysis covers Neurotrophic Keratopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Neurotrophic Keratopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Neurotrophic Keratopathy Therapies and Key Companies
• RGN-259: ReGenTree, LLC
• OC-01 (varenicline): Oyster Point Pharma, Inc.
• cenegermin-bkbj: Dompé Farmaceutici
• Udonitrectag: Syneos Health
• rhNGF: Dompé Farmaceutici
• REC 0559: Recordati Rare Diseases/MimeTech
• CSB-001: Claris Biotherapeutics
Discover more about therapies set to grab major Neurotrophic Keratopathy market share @ Neurotrophic Keratopathy Treatment Market
https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Neurotrophic Keratopathy Market Strengths
• Increasing prevalence of other conditions causes neurotrophic Keratopathy, thereby increasing NK population.
• The development of novel molecules potentially targets epithelial healing and corneal innervation
• Advances in biotechnology, laser and robotic treatment also aid in the treatment of Neurotrophic Keratopathy.
Neurotrophic Keratopathy Market Opportunities
• The recent approval of Oxervate by EMA and priority review designation approved by the USFDA will popularize the utilization of recombinant human nerve growth factors for the treatment of neurotrophic Keratopathy during the forecast period.
• Researchers are increasing their investments to develop and discover drugs that could potentially treat rare eye disease
Scope of the Neurotrophic Keratopathy Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Neurotrophic Keratopathy Companies: ReGenTree, LLC, Oyster Point Pharma, Inc., Dompé Farmaceutici, Syneos Health, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, and others
• Key Neurotrophic Keratopathy Therapies: RGN-259, OC-01 (varenicline), cenegermin-bkbj, Udonitrectag, rhNGF, REC 0559, CSB-001, and others
• Neurotrophic Keratopathy Therapeutic Assessment: Neurotrophic Keratopathy current marketed and Neurotrophic Keratopathy emerging therapies
• Neurotrophic Keratopathy Market Dynamics: Neurotrophic Keratopathy market drivers and Neurotrophic Keratopathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Neurotrophic Keratopathy Unmet Needs, KOL's views, Analyst's views, Neurotrophic Keratopathy Market Access and Reimbursement
To know more about Neurotrophic Keratopathy companies working in the treatment market, visit @ Neurotrophic Keratopathy Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Neurotrophic Keratopathy Market Report Introduction
2. Executive Summary for Neurotrophic Keratopathy
3. SWOT analysis of Neurotrophic Keratopathy
4. Neurotrophic Keratopathy Patient Share (%) Overview at a Glance
5. Neurotrophic Keratopathy Market Overview at a Glance
6. Neurotrophic Keratopathy Disease Background and Overview
7. Neurotrophic Keratopathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Neurotrophic Keratopathy
9. Neurotrophic Keratopathy Current Treatment and Medical Practices
10. Neurotrophic Keratopathy Unmet Needs
11. Neurotrophic Keratopathy Emerging Therapies
12. Neurotrophic Keratopathy Market Outlook
13. Country-Wise Neurotrophic Keratopathy Market Analysis (2019-2032)
14. Neurotrophic Keratopathy Market Access and Reimbursement of Therapies
15. Neurotrophic Keratopathy Market Drivers
16. Neurotrophic Keratopathy Market Barriers
17. Neurotrophic Keratopathy Appendix
18. Neurotrophic Keratopathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Neurotrophic Keratopathy Pipeline https://www.delveinsight.com/report-store/neurotrophic-keratopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Neurotrophic Keratopathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Neurotrophic Keratopathy market. A detailed picture of the Neurotrophic Keratopathy pipeline landscape is provided, which includes the disease overview and Neurotrophic Keratopathy treatment guidelines.
Neurotrophic Keratopathy Epidemiology https://www.delveinsight.com/report-store/neurotrophic-keratopathy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Neurotrophic Keratopathy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Neurotrophic Keratopathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
• Post Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• HiPost Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• Hip Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
• Amblyopia Market: https://www.delveinsight.com/report-store/amblyopia-market
• Type 2 Diabetes Market: https://www.delveinsight.com/report-store/diabetes-market
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurotrophic Keratopathy Market to Expand Significantly by 2032, States DelveInsight Report | ReGenTree, LLC, Oyster Point Pharma, Inc., Dompé Farmaceutici, Syneos Health here
News-ID: 4016678 • Views: …
More Releases from DelveInsight Business Research
Von Willebrand Disease Market Insights Highlight Expanding Outlook Till 2034, De …
DelveInsight's "Von Willebrand Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Von Willebrand Disease, historical and forecasted epidemiology as well as the Von Willebrand Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Von Willebrand Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Von Willebrand Disease…
Global Artificial Kidney Market to reach USD 6.09 billion by 2032 at a CAGR of 1 …
According to DelveInsight's analysis, The growing demand for artificial kidneys is primarily fueled by the increasing prevalence of kidney failure and end-stage renal disease (ESRD), alongside a rising incidence of contributing factors such as diabetes, hypertension, and an aging global population. These trends are driving the need for advanced and efficient renal care technologies. Moreover, the expanding preference for home-based dialysis solutions, combined with continuous technological innovations and frequent product…
Global Bladder Scanners Market to grow at a CAGR of 6.12% by 2032, Evaluates Del …
According to DelveInsight's analysis, The growing prevalence of urinary disorders such as incontinence, urinary retention, and overactive bladder especially among the aging population continues to drive demand for bladder scanners. The increasing preference for non-invasive and efficient diagnostic tools is further propelling market growth, as bladder scanners provide a safe, quick, and accurate alternative to traditional catheterization. Their expanding use across hospitals, clinics, and home care settings highlights their clinical…
Global Transdermal Drug Delivery Devices Market to reach USD 121,798.76 million …
According to DelveInsight's analysis, The rising incidence of chronic diseases, along with the growing adoption of advanced third-generation transdermal drug delivery systems, is substantially driving the global market's growth.
DelveInsight's "Transdermal Drug Delivery Devices Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Transdermal Drug Delivery Devices…
More Releases for Keratopathy
Neurotrophic Keratopathy Market is expected to reach USD 540 million by 2034
Neurotrophic keratopathy (NK) is a rare, degenerative corneal disease caused by impaired corneal innervation, leading to reduced or absent corneal sensitivity. It results in epithelial breakdown, impaired healing, corneal ulceration, and in severe cases, vision loss. Common causes include herpes simplex/zoster infection, diabetes, ocular surgery, multiple sclerosis, and trigeminal nerve damage.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72289
With the rising incidence of ocular surgeries, viral infections, and diabetes,…
Bullous Keratopathy Market is expected to reach USD 755 million by 2034
Bullous keratopathy is a progressive corneal disorder characterized by corneal endothelial cell dysfunction, leading to corneal edema, blister-like formations, and painful vision loss. It is most commonly associated with aging, cataract surgery complications, and conditions such as Fuchs' endothelial dystrophy. Left untreated, bullous keratopathy can cause severe visual impairment, making it a significant cause of corneal blindness worldwide.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72223
As the global burden…
How the Bullous Keratopathy Market Evolve by 2032 - Growth, Segments, and Revenu …
Bullous Keratopathy Market is estimated to be valued at USD 1.62 Bn in 2025 and is expected to reach USD 2.92 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032.
The Bullous Keratopathy Market : A thorough analysis of statistics about the current as well as emerging trends offers clarity regarding the Bullous Keratopathy Market dynamics. The report includes Porter's Five Forces to…
Neurotrophic Keratopathy Drugs Market 2032: Clinical Trials, EMA, PDMA, FDA Appr …
(Albany, USA) DelveInsight's "Neurotrophic Keratopathy Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Neurotrophic Keratopathy, historical and forecasted epidemiology as well as the Neurotrophic Keratopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Neurotrophic Keratopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurotrophic Keratopathy Market Forecast
https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the…
Neurotrophic Keratopathy Drugs Market 2032: Clinical Trials, EMA, PDMA, FDA Appr …
(Albany, USA) DelveInsight's "Neurotrophic Keratopathy Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Neurotrophic Keratopathy, historical and forecasted epidemiology as well as the Neurotrophic Keratopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Neurotrophic Keratopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurotrophic Keratopathy Market Forecast
https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the…
Bullous Keratopathy Market Poised for Robust Growth at an 11.5% CAGR Over the Co …
The bullous keratopathy treatment market is projected to experience substantial growth over the coming decade, driven by an aging population, increasing prevalence of cataract surgeries, glaucoma procedures, and novel pharmaceutical interventions by key bullous keratopathy players such as Aurion Biotechnologies, Emmecell, Trefoil Therapeutics, and Cellusion, among others.
DelveInsight's "Bullous Keratopathy Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/bullous-keratopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers an in-depth understanding of bullous keratopathy, historical and forecasted epidemiology,…
